The fourth annual “Cataract Surgery: Telling It Like It Is!” meeting here Jan. 16 to 19, 2014, promises to cover more ground than ever-adding sessions on glaucoma, retina, optical coherence tomography, cornea, neuro-ophthalmology, and practice management.
Universal use of intracameral antibiotics can nearly eliminate postoperative endophthalmitis, relates one ophthalmologist.
An in-house financing program can provide many benefitscan grow the business in terms of the number of procedures performed, while saving money paid in third-party discounts, and even create new revenue streams as interest comes in on monthly payments.
A new letter contrast sensitivity test may aid in the evaluation of patients with age-related macular degeneration and other retinal diseases.
Including checks and balances in ophthalmic practices’ electronic health record systems can help ensure proper coding.
A 12-year-old boy presents with full thickness macular hole 6 weeks after trauma to the left eye. What to do next?
Many new products and updated devices were presented during this year’s ESCRS meeting and EURETINA 2013.
While marking its 40th anniversary this year, the LEITR recognized its many achievements while also laying out its plans moving forward.
An ophthalmologist explains how he and some colleagues have had excellent success with a new combination procedure ICE: iStent, Cataract, and Endocyclophotocoagulation.
Children are particularly sensitive to systemic side effects of topical glaucoma medications for a variety of reasons. Increased caution is necessary when using these agents.
Achieving alignment of strabismus can be difficult in children with syndromic craniosynostosis as the causes are multifactorial.
Recent randomized clinical trials have been advancing the understanding of current treatments for convergence insufficiency. More prospective studies are needed to investigate convergence types and their roles in convergence insufficiency.
Phase II clinical study results indicate monthly lampalizumab therapy may be successful treatment
Baylor College of Medicine (BCM) has named Timothy Stout, MD, PhD, as its new ophthalmology department chairman.
InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan Inc.
Sucampo has announced that its development partner, R-Tech Ueno Ltd., has completed the enrollment of a phase III study for its treatment of retinitis pigmentosa (RP).
Prevent Blindness America (PBA) and several of its partners have joined together to launch a new initiative called the “Year of Children’s Vision” (YOCV).
Flap-related complications associated with mechanical microkeratomes are fewer with femtosecond laser-created flaps, according to Perry S. Binder, MS, MD.
Obamacare’s provision stating vision services for children are essential will help increase the number of young people able to receive check-ups and follow-up care, which are crucial for their well being.
Inclusion of clinically relevant genetic markers improves the accuracy of predicting risk of progression to choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD) beyond a prediction based on only phenotypic risk factors, according to a recent cohort study.
Alimera Sciences Inc. has received a complete response letter (CRL) for the new drug application (NDA) for its sustained-release intravitreal implant, Iluvien, from the FDA.
The FDA has cleared the use of corneal and arcuate incisions on Ziemer Ophthalmic Systems’ femtosecond laser platform during cataract surgery.
The final early benefit assessment from the German Federal Joint Committee (G-BA) has concluded that ThromboGenics’ ocriplasmin (Jetrea) demonstrates significant added benefit for vitreomacular traction (VMT) patients with mild and moderate symptoms.
The American Academy of Ophthalmology (AAO) has announced its newly redesigned Ophthalmic News and Education (ONE) Network, an online source of peer-reviewed news and education for ophthalmologists.
The FDA has approved Allegro Ophthalmics’ investigational new drug application to begin phase II clinical studies of ALG-1001, an integrin peptide therapy.
Omeros Corp. has announced that the new drug application (NDA) for its new product, OMS302, has been confirmed for filing by the FDA.
Refractive surgery is a safe method for correcting refractive error, according to a retrospective review of all cases of the surgery performed over a 7-year period at a U.S. military laser refractive surgery center.
In my practice ORA is invaluable, and I can’t imagine performing surgery without it. The technology has evolved greatly since the first-generation system was introduced, and its accuracy amazes me.
The 2013 Ophthalmology Innovation Summit will convene Nov. 14 in New Orleans. Visit www.ophthalmologysummit.com for updates or to register.
.png "Optometry Times"){kind=logo}
